For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Fulcrum Therapeutics Inc (NASDAQ: FULC) was $9.98 for the day, down -0.10% from the previous closing price of $9.99. In other words, the price has decreased by -$0.10 from its previous closing price. On the day, 1.0 million shares were traded. FULC stock price reached its highest trading level at $10.45 during the session, while it also had its lowest trading level at $9.77.
Ratios:
Our analysis of FULC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 17.70 and its Current Ratio is at 17.70. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
On July 29, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4 to $12.
Leerink Partners Upgraded its Market Perform to Outperform on May 23, 2025, while the target price for the stock was maintained at $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 02 ’26 when Gould Robert J sold 15,000 shares for $11.87 per share. The transaction valued at 178,089 led to the insider holds 469,864 shares of the business.
Oltmans Curtis Gale sold 3,452 shares of FULC for $44,600 on Dec 15 ’25. The Chief Legal Officer now owns 10,252 shares after completing the transaction at $12.92 per share. On Dec 15 ’25, another insider, CURTIS G OLTMANS, who serves as the Officer of the company, bought 3,452 shares for $13.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FULC now has a Market Capitalization of 658383488 and an Enterprise Value of 346468000.
Stock Price History:
The Beta on a monthly basis for FULC is 3.18, which has changed by 1.2860413 over the last 52 weeks, in comparison to a change of 0.19182634 over the same period for the S&P500. Over the past 52 weeks, FULC has reached a high of $15.74, while it has fallen to a 52-week low of $2.32. The 50-Day Moving Average of the stock is -5.22%, while the 200-Day Moving Average is calculated to be 32.54%.
Shares Statistics:
FULC traded an average of 1.31M shares per day over the past three months and 760880 shares per day over the past ten days. A total of 65.97M shares are outstanding, with a floating share count of 59.86M. Insiders hold about 9.27% of the company’s shares, while institutions hold 67.40% stake in the company. Shares short for FULC as of 1765756800 were 2994328 with a Short Ratio of 2.28, compared to 1763078400 on 3564671. Therefore, it implies a Short% of Shares Outstanding of 2994328 and a Short% of Float of 6.0700003.
Earnings Estimates
Fulcrum Therapeutics Inc (FULC) is presently subject to a detailed evaluation by 10.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.21 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.13 and -$1.21 for the fiscal current year, implying an average EPS of -$1.17. EPS for the following year is -$1.2, with 10.0 analysts recommending between -$0.85 and -$1.52.
